To our knowledge, this is the first clinical trial to prospectively report that the combination of low-dose nab-paclitaxel and tislelizumab is well tolerated and leads to promising outcomes in elderly patients with advanced NSCLC, including patients with EGFR or ALK variations. This evidence concerns the gene ALK and non-small cell lung carcinoma.